Abstract
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have